CTLA4 and type 1 diabetes mellitus: When considering all patients treated with combination regimens as one group (anti-CTLA4 or other agents), median time to ICI-induced IDDM onset was not statistically different from patients treated with monotherapy (1.4 vs. 3.9 months, p = 0.07).